Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
References
EntrestoⓇ
1 IQVIA National Prescription Audit.
2 Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal."
(US), HFrEF (EU), HFrEF and HTN (China) and CHF and HTN (JP). HTN is not an approved indication in the US.
AHA/ACC/HFSA/ESC
3
4 Pediatric indication would support extension of the regulatory data protection to November 2026 in EU
5 Primary endpoint: NT-proBNP in HFPEF. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure
KesimptaⓇ
1 Rolling 4 weeks. 1 June 2023, IQVIA NPA (KesimptaⓇ) and IQVIA NPA adjusted by NSP (all others). B-cell therapies as portion of MS market in NBRx.
2 Data on file.
3
4
The initial dosing period consists of 20 mg subcutaneous doses at Weeks 0, 1 and 2, thereafter once a month. Patient must take pen out of the refrigerator 15-30 minutes before self-administering.
Efficacy outcomes as measured by disability progression and brain volume change.
5 Cohen et al, Poster presented at American Academy of Neurology, Boston, 22-27 April 23.
6
Cohen et al, oral presentation at American Academy of Neurology, Boston, 22-27 April 23.
90 Investor Relations | Q2 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation